MacroGenics, Inc. (NASDAQ:MGNX) to Post Q1 2025 Earnings of ($0.76) Per Share, HC Wainwright Forecasts

MacroGenics, Inc. (NASDAQ:MGNX) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of MacroGenics in a research report issued on Monday, May 13th. HC Wainwright analyst R. Burns anticipates that the biopharmaceutical company will post earnings per share of ($0.76) for the quarter. HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for MacroGenics’ current full-year earnings is ($2.90) per share. HC Wainwright also issued estimates for MacroGenics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.82) EPS and FY2025 earnings at ($3.16) EPS.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.17). The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $13.63 million. MacroGenics had a negative net margin of 53.60% and a negative return on equity of 98.01%.

A number of other research analysts have also issued reports on MGNX. BMO Capital Markets lowered MacroGenics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $24.00 to $8.00 in a report on Friday, May 10th. TheStreet lowered MacroGenics from a “c” rating to a “d” rating in a report on Thursday, March 7th. JMP Securities decreased their price target on MacroGenics from $22.00 to $16.00 and set a “market outperform” rating for the company in a research report on Friday, May 10th. B. Riley initiated coverage on MacroGenics in a research report on Friday, April 26th. They issued a “buy” rating and a $25.00 price target for the company. Finally, Barclays decreased their price objective on MacroGenics from $25.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, May 10th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, MacroGenics currently has an average rating of “Moderate Buy” and an average target price of $13.67.

MacroGenics Stock Up 5.8 %

NASDAQ:MGNX opened at $4.71 on Tuesday. The business’s 50-day moving average price is $15.01 and its 200 day moving average price is $12.65. The firm has a market cap of $294.99 million, a P/E ratio of -12.08 and a beta of 2.09. MacroGenics has a 52-week low of $3.14 and a 52-week high of $21.88.

Insider Activity at MacroGenics

In other news, VP Jeffrey Stuart Peters sold 51,395 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.55, for a total transaction of $799,192.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.30% of the stock is owned by company insiders.

Institutional Trading of MacroGenics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in MacroGenics by 8,361.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,438,050 shares of the biopharmaceutical company’s stock valued at $35,889,000 after acquiring an additional 2,409,237 shares during the period. Avoro Capital Advisors LLC acquired a new position in MacroGenics in the first quarter worth $90,528,000. EntryPoint Capital LLC acquired a new position in MacroGenics in the first quarter worth $40,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of MacroGenics during the first quarter worth $52,000. Finally, ProShare Advisors LLC boosted its stake in shares of MacroGenics by 8.9% in the 1st quarter. ProShare Advisors LLC now owns 15,282 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 1,246 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.